Evidence map›Paper›PMID 42458865›Full record

ArticleSmall methods2026

A Dual-Responsive Claringbullite-Like Nanozyme for Inhibition of Non-Small Cell Lung Cancer Progression.

Xu Chen, Tianle Yang, Wenjie Zheng, Yingyi Luo, Ruixue Liang, Sanqi An, Xinli Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xu ChenLife Sciences Institute, Guangxi Medical University, Nanning, China.
Tianle YangLife Sciences Institute, Guangxi Medical University, Nanning, China.
Wenjie ZhengDepartment State Key Laboratory of High-efficiency Utilization of Coal and Green Chemical Engineering, School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, China.ORCID https://orcid.org/0009-0009-0823-6062
Yingyi LuoLife Sciences Institute, Guangxi Medical University, Nanning, China.
Ruixue LiangLife Sciences Institute, Guangxi Medical University, Nanning, China.
Sanqi AnLife Sciences Institute, Guangxi Medical University, Nanning, China.ORCID https://orcid.org/0000-0002-3177-213X
Xinli LiuLife Sciences Institute, Guangxi Medical University, Nanning, China.ORCID https://orcid.org/0000-0002-0185-0950

Funding

Guangxi Medical University Training Program for Distinguished Young ScholarsGuangxi Natural Science Foundation 2025GXNSFAA069953Guangxi Science and Technology Program GuikeAD23026189Middle / Young aged Teachers' Research Ability Improvement Project of Guangxi Higher Education 2024KY0114
6 · The paper itself

Abstract

A Claringbullite-like nanozyme CuCl

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsA549 CellsAnimalsCuproptosisDisease ProgressionFerroptosisGlutathioneHumansMiceAntineoplastic AgentsGlutathioneanti‐tumor immune responsescuproptosisferroptosisnanozymetumor catalytic therapy

Identifiers

PMID42458865
PMCPMC13450361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.